Eli Lilly discovers, develops, manufactures, and markets human pharmaceutical products in a single business segment, with medicines sold in approximately 90 countries. Its cardiometabolic health franchise leads the portfolio, anchored by the incretin medicines Mounjaro for type 2 diabetes and Zepbound for obesity and obstructive sleep apnea, alongside Trulicity, Jardiance, and insulins. Other therapeutic areas include oncology (Verzenio for breast cancer, Jaypirca, Retevmo), immunology (Taltz, Omvoh, Ebglyss), and neuroscience (Kisunla for early Alzheimer's disease, Emgality for migraine). Founded in 1876 and incorporated in Indiana in 1901, Lilly manufactures and distributes through facilities in the United States, Europe, and Asia and continues to invest heavily in expanding manufacturing capacity for its incretin medicines.

Piotroski F-Score

Beneish M-Score

Operating Margin %

Revenue per Share

Altman Z-Score

Long-Term Debt

Insider Sell

Price

PS Ratio

Dividend Yield %

Eli Lilly and Co